ICON plc entered into a definitive agreement to sell its commercial healthcare data business, Symphony Health Solutions Corporation, to HealthVerity, Inc. The transaction is structured as a cash‑and‑stock deal and is expected to close in May 2026. The purchase price was not disclosed.
The sale allows ICON to streamline its focus on core clinical research services, while HealthVerity will enhance its real‑world evidence capabilities by integrating Symphony Health’s commercial data platform. "For more than 30 years, Symphony Health has been a trusted source of commercial healthcare data. Symphony will bring this scale and expertise to the combination with..." said Simon Holmes, President of Corporate Investments & Partnerships at ICON.
HealthVerity CEO Andrew Kress added, "This transaction will create the nation's leading patient‑centric real‑world and commercial data ecosystem within a privacy‑safe, modern infrastructure." The deal positions HealthVerity to offer a more comprehensive view of patients by combining clinical depth with commercial insights at scale.
Symphony Health was acquired by PRA Health Sciences in August 2017 for $530 million and subsequently purchased by ICON in September 2017. The unit’s estimated annual revenue has ranged from $64 million to over $200 million in prior years, and HealthVerity has raised $142 million in funding through a Series D round in 2021.
The transaction aligns with a broader industry trend of companies focusing on core competencies and divesting non‑core assets. It is expected to be accretive to ICON’s earnings in the long term by reducing operating costs and freeing capital for technology and clinical service initiatives. Both companies anticipate that the integration will strengthen their respective data ecosystems and support future growth.
The deal represents a significant strategic pivot for ICON and a major expansion for HealthVerity, with both firms poised to benefit from the combined data capabilities and market reach. The transaction is expected to close in May 2026, with the purchase price remaining undisclosed.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.